Although numerous genetic variations in lipid metabolism genes are known to be associated with atherosclerosis (26), three main molecular targets were chosen to develop genetically modified animal models: LDL receptor (LDLr), apolipoprotein E, and proprotein convertase subtilisin/kexin type 9 (PCSK9). Here, PCSK9 is linked to atherosclerosis.